Harmony Biosciences buys small epilepsy biotech for $35M, plus milestones

Rare neurological disease drug developer Harmony Biosciences acquired Epygenix Therapeutics and its pipeline of treatments for rare epilepsy conditions.

Harmony paid $35 million upfront, and could pay another $130 million in development and regulatory milestones, according to a press release. The deal also includes sales-based payments that could be as much as $515 million.

Kumar Budur

With the acquisition, Harmony adds the antihistamine clemizole hydrochloride to its pipeline. Research from the University of California, San Francisco showed that the drug is also a serotonin receptor agonist with anti-epileptic activity, Harmony’s chief medical officer Kumar Budur said on an analyst call Tuesday.

The treatment is currently in a pivotal study for Dravet syndrome, a genetic form of epilepsy that typically starts in infancy or early childhood, with data expected in 2026. The company also plans to launch a…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks